Medidata AI’s Synthetic Control Arm® (SCA®) leverages historical clinical trial data (HCTD) to provide a more relevant clinical insight for the purpose of developing new therapies. In comparison to RWD, HCTD based SCAs utilize “regulatory grade” data, …

… the Phase 1/2a Glioblastoma Multiforme (GBM) uMGMT trial shows an … 1 trial for newly diagnosed Glioblastoma Multiforme patients with an unmethylated MGMT …

… the classification of the Glioblastoma Multiforme Treatment market, highlighting significant … , and trends shaping the Glioblastoma Multiforme Treatment industry. • It … businesses navigate the Global Glioblastoma Multiforme Treatment market effectively. • …

… leronlimab in the treatment of glioblastoma multiforme (“GBM”). A preclinical study at …

… (55%). Glioblastoma Multiforme Treatment Market Highlights: North America led the glioblastoma multiforme treatment market … hemisphere glioma. Glioblastoma Multiforme Treatment Market Regional Outlook U.S. Glioblastoma Multiforme Treatment Market …

… , glioblastoma multiforme (GBM) treatment market major players, glioblastoma multiforme (GBM) treatment competitors' revenues, glioblastoma multiforme …

… life for patients suffering from glioblastoma multiforme and metastatic brain tumors. The …

… , was diagnosed with stage four glioblastoma multiforme in 2017 and suffers with … October 2017 with stage four Glioblastoma Multiforme (above) Mr Pearce has told …

… DaRT for patients with recurrent glioblastoma multiforme (“GBM”). This acceptance follows the …